Answers are grounded in this paper and cite their sources.
This review highlights advances in inhibitor design and therapeutic strategies for overcoming tumor resistance in oncology.
Aldo-keto reductase 1B10 (AKR1B10), a key member of the aldehyde-ketone reductase superfamily, plays crucial roles in tumorigenesis, chemotherapy resistance, and metabolic regulation. However, the clinical translation of its inhibitors has been persistently hindered by off-target toxicities arising from highly homologous enzymes and severe competition from intracellular substrates. This review critically summarizes the paradigm shift in AKR1B10-targeted drug discovery. From a structural pharmacology perspective, we systematically elucidate how inhibitor design has evolved from classical anion-binding pocket (ABP) anchoring to pocket-specific designs that exploit the topological differences of subpockets (LAS/SP) to overcome subtype selectivity barriers. Furthermore, to bypass the inherent limitations of reversible competitive inhibition, we prospectively explore next-generation therapeutic modalities, including targeted protein degradation (PROTACs), covalent modifiers, and small molecule-drug conjugates (SMDCs), alongside multitarget combination regimens aimed at systematically dismantling tumor resistance networks. Ultimately, this review aims to provide breakthrough insights to overcome current clinical bottlenecks, providing a reference for the future development of novel, highly efficacious precision oncology therapeutics.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: